Timothy D. Henry

Active 1990–2025

214
Papers
35,240
Citations
98
h-index
204
i10-index

Citations

Citations per year for Timothy D. Henry1992: 2 citations1993: 2 citations1994: 8 citations1995: 16 citations1996: 12 citations1997: 7 citations1998: 10 citations1999: 18 citations2000: 17 citations2001: 35 citations2002: 32 citations2003: 51 citations2004: 89 citations2005: 72 citations2006: 53 citations2007: 90 citations2008: 95 citations2009: 100 citations2010: 145 citations2011: 174 citations2012: 186 citations2013: 223 citations2014: 173 citations2015: 202 citations2016: 202 citations2017: 218 citations2018: 217 citations2019: 691 citations2020: 1,913 citations2021: 1,507 citations2022: 904 citations2023: 652 citations2024: 1,063 citations2025: 564 citations2026: 22 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,318 citing papers, 25.4% of this breakdownUnited Kingdom: 855 citing papers, 6.6% of this breakdownItaly: 810 citing papers, 6.2% of this breakdownChina: 741 citing papers, 5.7% of this breakdownGermany: 719 citing papers, 5.5% of this breakdownCanada: 574 citing papers, 4.4% of this breakdownFrance: 488 citing papers, 3.7% of this breakdownNetherlands: 398 citing papers, 3% of this breakdownSpain: 387 citing papers, 3% of this breakdownJapan: 378 citing papers, 2.9% of this breakdownSwitzerland: 313 citing papers, 2.4% of this breakdownAustralia: 294 citing papers, 2.3% of this breakdown
0%25.4%Other 28.9%

Fields

  • Medicine71.4%
  • Biochemistry, Genetics and Molecular Biology12%
  • Engineering9.4%
  • Neuroscience1.2%
  • Immunology and Microbiology1.1%
  • Materials Science0.9%
  • Other4%

Topics

  • Acute Myocardial Infarction Research6.3%
  • Mechanical Circulatory Support Devices4.4%
  • Coronary Interventions and Diagnostics4.1%
  • COVID-19 Clinical Research Studies3.9%
  • Tissue Engineering and Regenerative Medicine3.8%
  • Mesenchymal stem cell research3.4%
  • Other74.1%

Coauthors

All papers

Open in search
  1. Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association

    Authors: , , , , , , , , , , , , - Circulation 2017 cited by 1,801

  2. SCAI clinical expert consensus statement on the classification of cardiogenic shock

    Authors: , , , , , , , , , , , , , - Catheterization and Cardiovascular Interventions 2019 cited by 1,014

  3. Ticagrelor with or without Aspirin in High-Risk Patients after PCI

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Gabríel Steg, Giora Weisz, Bernhard Witzenbichler, Yaling Han, Stuart Pocock, C. Michael Gibson - New England Journal of Medicine 2019 cited by 1,000

  4. Colchicine in Acute Myocardial Infarction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2024 cited by 260

  5. Cardiogenic Shock Classification to Predict Mortality in the Cardiac Intensive Care Unit

    Authors: , , , , , , , - Journal of the American College of Cardiology 2019 cited by 540

  6. First-in-Man Study of a Cardiac Extracellular Matrix Hydrogel in Early and Late Myocardial Infarction Patients

    Authors: , , , , , , , , , - JACC Basic to Translational Science 2019 cited by 303

  7. Invasive Management of Acute Myocardial Infarction Complicated by Cardiogenic Shock: A Scientific Statement From the American Heart Association

    Authors: , , , , , , , , , , - Circulation 2021 cited by 257

  8. Comprehensive Management of ANOCA, Part 1—Definition, Patient Population, and Diagnosis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2023 cited by 164

  9. A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Intravenous Adult Human Mesenchymal Stem Cells (Prochymal) After Acute Myocardial Infarction

    Authors: , , , , , , , , , , , , , - Journal of the American College of Cardiology 2009 cited by 1,348

  10. Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Philippe Gabríel Steg, Giora Weisz, Bernhard Witzenbichler, Yaling Han, Stuart Pocock, C. Michael Gibson, Roxana Mehran - European Heart Journal 2020 cited by 176

  11. A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michelle Cohen, Lara M. Simpson, David Aguilar, Cătălin Loghin, Lem Moyé, Ray F. Ebert, Barry R. Davis, Robert D. Simari - European Journal of Heart Failure 2021 cited by 166

  12. Defining Shock and Preshock for Mortality Risk Stratification in Cardiac Intensive Care Unit Patients

    Authors: , , , , , , , , , , , - Circulation Heart Failure 2021 cited by 107

  13. Randomized Trial of Targeted Transendocardial Mesenchymal Precursor Cell Therapy in Patients With Heart Failure

    Authors: , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2023 cited by 88

  14. Treatment Time and In-Hospital Mortality Among Patients With ST-Segment Elevation Myocardial Infarction, 2018-2021

    Authors: , , , , , , , , , , , , - JAMA 2022 cited by 100

  15. Artificial Intelligence Can Improve Patient Management at the Time of a Pandemic: The Role of Voice Technology

    Authors: , , , , , - Journal of Medical Internet Research 2021 cited by 80

  16. Comprehensive Management of ANOCA, Part 2—Program Development, Treatment, and Research Initiatives

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2023 cited by 64

  17. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents

    Authors: , , , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2016 cited by 548

  18. Relationship Between Intravascular Ultrasound Guidance and Clinical Outcomes After Drug-Eluting Stents

    Authors: , , , , , , , , , , , , , , , , - Circulation 2013 cited by 410

  19. Efficacy of a Device to Narrow the Coronary Sinus in Refractory Angina

    Authors: , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2015 cited by 296

  20. Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention

    Authors: , , , , , , , , , , , , , , , , , , - Journal of the American College of Cardiology 2015 cited by 448

  21. Systemic Inflammatory Response Syndrome Is Associated With Increased Mortality Across the Spectrum of Shock Severity in Cardiac Intensive Care Patients

    Authors: , , , , , , , , , - Circulation Cardiovascular Quality and Outcomes 2020 cited by 105

  22. Intracoronary Gene Transfer of Adenylyl Cyclase 6 in Patients With Heart Failure

    Authors: , , , , , , , , , , , , , , , , , , , - JAMA Cardiology 2016 cited by 138

  23. Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction

    Authors: , , , , , , , , , , , , , , , , - Circulation Cardiovascular Interventions 2022 cited by 51

  24. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study

    Authors: , , , , , , , , , , , , , , , , - The Lancet 2013 cited by 851